Effects of Ganopoly® (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients

Gao, Y, Zhou, S, Jiang, W, Huang, M and Dai, X 2003, 'Effects of Ganopoly® (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients', Immunological Investigations, vol. 32, no. 3, pp. 201-215.


Document type: Journal Article
Collection: Journal Articles

Title Effects of Ganopoly® (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients
Author(s) Gao, Y
Zhou, S
Jiang, W
Huang, M
Dai, X
Year 2003
Journal name Immunological Investigations
Volume number 32
Issue number 3
Start page 201
End page 215
Total pages 15
Publisher Informa Healthcare
Abstract Preclinical studies have established that the Ganoderma lucidum polysaccharide (GLPS) fractions have potent anti-tumor activity, which has been associated with the immuno-stimulating effects of GLPS. However, it is unclear whether GLPS has immuno-modulating effects in humans in vivo. This study aimed to investigate the effects of Ganopoly®, the polysaccharides fractions extracted from G. lucidum, on the immune function of advanced-stage cancer patients. Thirty-four advance-stage cancer patients were entered onto this study, and treated with 1800 mg Ganopoly®, three times daily orally before meals for 12 weeks. Immune parameters (cytokines, T cell subsets, mitotic response to phytohemagglutinin (PHA) and natural killer (NK) activity) were compared between baseline and after 12-week treatment. Thirty patients are assessable for their immune functions. Treatment of Ganopoly® for 12 weeks resulted in a significant (P < 0.05) increase in the mean plasma concentrations of interleukin (IL-2), IL-6, and interferon (IFN)-?, whereas the levels of IL-1 and tumor necrosis factor (TNF-a) were significantly (P < 0.05) decreased. A marked variability among patients with advanced-stage cancer was observed in the numbers of each lymphocyte subset at baseline. The mean absolute number of CD56+ cells was significantly (P < 0.05) increased after 12-week treatment of Ganopoly®, whereas the numbers of CD3+, CD4+, and CD8+ were just marginally increased compared to baseline levels, with the CD4:CD8 T cell ratios unchanged. PHA responses after 12-week treatment with Ganopoly® were enhanced in most patients, when compared to pretreatment baselines (P < 0.05). In addition, Ganopoly® treatment resulted in a significant increase (P < 0.05) in the mean NK activity compared to baselines (34.5 ± 11.8% vs 26.6 ± 8.3%). The present study indicates that Ganopoly® enhanced the immune responses in patients with advanced-stage cancer. Clinical evaluations of response and toxicity are ongoing.
Keyword(s) efficacy
ganoderma lucidum
polysaccharide
safety
tumor
DOI - identifier 10.1081/IMM-120022979
ISSN 0882-0139
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 155 times in Scopus Article | Citations
Altmetric details:
Access Statistics: 239 Abstract Views  -  Detailed Statistics
Created: Mon, 06 Dec 2010, 14:11:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us